Showing results (1471-1480 of 1,500) with videos related to
Sort By:
Pageof 150
Frontiers in Pharmacology|August 27, 2019
Does Routine Anti-Osteoporosis Medication Lower the Risk of Fractures in Male Subjects? An Updated Systematic Review With Meta-Analysis of Clinical TrialsLing-Feng Zeng, Bi-Qi Pan, Gui-Hong Liang, et al.Cell Metabolism|September 18, 2024
PDIA3 defines a novel subset of adipose macrophages to exacerbate the development of obesity and metabolic disordersJia-Hui Luo, Fa-Xi Wang, Jia-Wei Zhao, et al.Gastrointestinal Endoscopy|August 15, 2024
Development and validation of a machine learning-based, point-of-care risk calculator for post-ERCP pancreatitis and prophylaxis selectionTodd Brenner, Albert Kuo, Christina J Sperna Weiland, et al.Frontiers in Endocrinology|March 3, 2020
Can Dietary Intake of Vitamin C-Oriented Foods Reduce the Risk of Osteoporosis, Fracture, and BMD Loss? Systematic Review With Meta-Analyses of Recent StudiesLing-Feng Zeng, Ming-Hui Luo, Gui-Hong Liang, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2025
Radiation Dose-Volume Effects on Negative Tumor-Draining Lymph Nodes Affected T-cell Activation and Prognosis in Esophageal Cancer with ChemoradiotherapyIhsuan Tseng, Yun Chen, Dashan Ai, et al.Nature Medicine|February 1, 2024
First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 studyJin Li, Zhendong Chen, Yuxian Bai, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 5, 2018
Rectal Indomethacin and Spraying of Duodenal Papilla With Epinephrine Increases Risk of Pancreatitis Following Endoscopic Retrograde CholangiopancreatographyHui Luo, Xiangping Wang, Rongchun Zhang, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 19, 2021
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 TrialShengxiang Ren, Jianhua Chen, Xingxiang Xu, et al.Annals of the Rheumatic Diseases|February 7, 2025
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trialJinjing Liu, Ying Jiang, Shangzhu Zhang, et al.Annals of the Rheumatic Diseases|November 27, 2024
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trialJinjing Liu, Ying Jiang, Shangzhu Zhang, et al.Pageof 150